Don Tracy

2 days ago | appliedclinicaltrialsonline.com | Don Tracy

Carvykti Delivers Long-Term Remission: One-third of patients in the CARTITUDE-1 trial achieved at least five years of treatment-free survival after a single CAR T-cell therapy infusion. Sustained Efficacy in High-Risk Patients: The trial included heavily pretreated and triple-class refractory populations, with median overall survival reaching over five years.

3 days ago | pharmaceuticalcommerce.com | Don Tracy

Forging a Brighter Future for Rare Disease Outcomes with Specialty Pharmacy UtilizationA Pharmaceutical Executive article explores how specialty pharmacy programs can significantly improve outcomes for patients with rare diseases—like cystic fibrosis—by providing faster access to treatment, better medication adherence, and personalized support that addresses the complex challenges of managing lifelong conditions.

4 days ago | pharmaceuticalcommerce.com | Don Tracy

Five Critical Challenges in Investigator Site Selection and How Clinical Data Science Can Solve ThemIn a Pharmaceutical Executive feature, Gen Li, founder, CEO, Phesi, outlines five key challenges hindering investigator site selection in clinical trials—including unreliable performance predictions and lack of real-world data—and explains how clinical data science and AI-driven tools can optimize site feasibility, reduce costs, and accelerate drug development.

5 days ago | appliedclinicaltrialsonline.com | Don Tracy |Andy Studna

June 3, 2025By In this video interview, Ron Lanton, partner, Lanton Law, highlights how tariffs on active pharmaceutical ingredients could affect resources for maintaining and accelerating R&D pipelines. In a recent video interview with Applied Clinical Trials, Ron Lanton, partner, Lanton Law, discussed the impact of drug cost increases on clinical research, predicting a reduction in government-sponsored trials due to higher R&D costs and potential funding cuts.

5 days ago | pharmaceuticalcommerce.com | Don Tracy

Preparing for the Pharma C-SuiteIn a Pharmaceutical Executive feature, Aileen Fernandes, Chief Business Officer at Arcellx, reflects on how her early roles at Morgan Stanley and Deloitte Consulting, combined with strategic career decisions and authentic leadership development, prepared her for biotechnology C-suite success and offers MBA students key advice on culture fit, building healthcare connections, and leveraging their education to shape fulfilling leadership paths.